UAE approves Renfok for vitiligo

The Emirates Foundation for Medicine announced its approval for the use of "Rinvoq" (Ombitasvir) to treat non-segmental vitiligo in adults and adolescents aged 12 and above, making it the first oral medication licensed for this condition in the UAE. The medication is administered once daily by mouth as a systemic treatment option. This approval comes within a modern regulatory framework aligned with global advancements, aimed at improving treatment outcomes and providing new options for patients. The U.S. Food and Drug Administration had previously approved the drug for other conditions, such as Crohn’s disease, but the UAE is the first country to extend its use to treat vitiligo.

articleDetails.fontSize.sizeحجم النص

تنويه: هذا ملخص تم إنشاؤه بواسطة الذكاء الاصطناعي

عرض المقال بالكامل